Glucocorticoid signaling in the cell: Expanding clinical implications to complex human behavioral and somatic disorders

Annals of the New York Academy of Sciences

Volumn 1179, Issue , 2009, Pages 153-166

  Chrousos, George P ^a,b   Kino, Tomoshige ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

CDK5; Glucocorticoid hypersensitivity; Glucocorticoid resistance; GR phosphorylation; Metabolic syndrome; Osteoporosis; Stress system

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ALLERGIC DISEASE; ATHEROSCLEROSIS; BEHAVIOR; BRAIN; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; CONFERENCE PAPER; CUSHING SYNDROME; CYTOKINE RELEASE; DEPRESSION; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; LIFE EXPECTANCY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRESS;

CELLS; CYCLIN-DEPENDENT KINASE 5; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; MENTAL DISORDERS; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; PHOSPHORYLATION; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 70449417568     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04988.x     Document Type: Conference Paper

References (77)

1. Chrousos, G.P. 2001. Glucocorticoid therapy. In Endocrinology and Metabolism. P. Flig & L. Frohman, Eds.: 609-632. McGraw-Hill. New York, NY.
2. Franchimont, D. et al. 2003. Glucocorticoids and inflammation revisited: the state of the art. NIH Clinical Staff Conference. Neuroimmunomodulation 10: 247-260.
3. Galon, J. et al. 2002. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16: 61-71.
4. Chrousos, G.P. 1998. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann. N. Y. Acad. Sci. 851: 311-335.
5. Ẅust, S. et al. 2004. Common polymorphisms in the glucocorticoid receptor gene are associated with adrenocortical responses to psychosocial stress. J. Clin. Endocrinol. Metab. 89: 565-573.
6. Buemann, B. et al. 1997. Abdominal visceral fat is associated with a BclI restriction fragment length polymorphism at the glucocorticoid receptor gene locus. Obes. Res. 5: 186-192.
7. Dobson,M.G. et al. 2001. TheN363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus. J. Clin. Endocrinol. Metab. 86: 2270-2274.
8. Huizenga, N.A. et al. 1998. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab. 83: 144-151.
9. Lin, R.C., W.Y. Wang & B.J. Morris. 1999. High penetrance, overweight, and glucocorticoid receptor variant: case-control study. BMJ 319: 1337-1338.
10. Panarelli, M. et al. 1998. Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. J. Clin. Endocrinol. Metab. 83: 1846-1852.
11. Rosmond, R. et al. 2000. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamicpituitary- adrenal axis. Obes. Res. 8: 211-218.
12. Ukkola, O. et al. 2001. Glucocorticoid receptor Bcl I variant is associated with an increased atherogenic profile in response to long-term overfeeding. Atherosclerosis 157: 221-224.
13. Weaver, J.U., G.A. Hitman & P.G. Kopelman. 1992. An association between a Bc1I restriction fragment length polymorphism of the glucocorticoid receptor locus and hyperinsulinaemia in obese women. J. Mol. Endocrinol. 9: 295-300.
14. Chrousos, G.P. 2000. The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann. N. Y. Acad. Sci. 917: 38-67.
15. Chrousos, G.P. 2000. The role of stress and the hypothalamic-pituitary- adrenal axis in the pathogenesis of themetabolic syndrome: neuro-endocrine and target tissue-related causes. Int. J. Obes. Relat. Metab. Disord. 24: S50-S55.
16. Chrousos, G.P., S.D. Detera-Wadleigh & M. Karl. 1993. Syndromes of glucocorticoid resistance. Ann. Intern. Med. 119: 1113-1124.
17. McEwen, B.S. 1998. Protective and damaging effects of stress mediators. N. Engl. J. Med. 338: 171-179.
18. Kino, T. et al. 2003. Tissue glucocorticoid resistance/ hypersensitivity syndromes. J. Steroid Biochem. Mol. Biol. 85: 457-467.
19. Charmandari, E. et al. 2008. Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J. Clin. Endocrinol. Metab. 93: 1563-1572.
20. Charmandari, E. et al. 2008. A novel point mutation in the DNA-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance. Endocrine 90: 280.
21. Chrousos, G.P. & P.W. Gold. 1992. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267: 1244-1252.
22. Gold, P.W. & G.P. Chrousos. 2002. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry 7: 254-275.
23. Alevizaki, M. et al. 2007. High anticipatory stress plasma cortisol levels and sensitivity to glucocorticoids predict severity of coronary artery disease in subjects undergoing coronary angiography. Metabolism 56: 222-226.
24. Chrousos, G.P. & T. Kino. 2005. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci. STKE 2005: pe48.
25. Kino, T., E. Charmandari & G.P. Chrousos. 2003. Basic and clinical implications of glucocorticoid action-focus on development. National Institutes of Health, Bethesda, Maryland, USA. June 17-18, 2003. Introduction and abstracts. Horm. Metab. Res. 35: 628-648.
26. Kino, T. et al. 2005. G protein â interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus. J. Cell Biol. 169: 885-896.
27. Kino, T., et al. 2006. Rho family guanine nucleotide exchange factor Brx couples extracellular signals to the glucocorticoid signaling system. J. Biol. Chem. 281: 9118-9126.
28. Kino, T. & G.P. Chrousos. 2003. Tumor necrosis factor á receptor- and Fas-associated FLASH inhibit transcriptional activity of the glucocorticoid receptor by binding to and interfering with its interaction with p160 type nuclear receptor coactivators. J. Biol. Chem. 278: 3023-3029.
29. Kino, T. et al. 2003. Protein 14-3-3ó interacts with and favors cytoplasmic subcellular localization of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signaling pathway. J. Biol. Chem. 278: 25651-25656.
30. Kino,T. et al. 1999.TheHIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J. Exp. Med. 189: 51-62.
31. Kino, T. et al. 2002. Human immunodeficiency virus type-1 accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J. Virol. 76: 9724-9734.
32. Ichijo, T. et al. 2005. The Smad6-histone deacetylase 3 complex silences the transcriptional activity of the glucocorticoid receptor: potential clinical implications. J. Biol. Chem. 280: 42067-42077.
33. Kino, T. et al. 2007. Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol. Endocrinol. 21: 1552-1568.
34. Kino, T. 2007. Tissue glucocorticoid sensitivity: beyond stochastic regulation on the diverse actions of glucocorticoids. Horm. Metab. Res. 39: 420-424.
35. Krstic, M.D. et al. 1997. Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol. Cell Biol. 17: 3947-3954.
36. Ismaili, N. & M.J. Garabedian. 2004. Modulation of glucocorticoid receptor function via phosphorylation. Ann. N. Y. Acad. Sci. 1024: 86-101.
37. Wang, Z., J. Frederick & M.J. Garabedian. 2002. Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo. J. Biol. Chem. 277: 26573-26580.
38. Miller, A.L. et al. 2005. p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and sitespecific phosphorylation of the human glucocorticoid receptor at serine 211. Mol. Endocrinol. 19: 1569-1583.
39. Itoh,M. et al. 2002. Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinasemediated phosphorylation. Mol. Endocrinol. 16: 2382-2392.
40. Ismaili, N., R. Blind & M.J. Garabedian. 2005. Stabilization of the unliganded glucocorticoid receptor by TSG101. J. Biol. Chem. 280: 11120-11126.
41. Kesavapany, S., B.S. Li & H.C. Pant. 2003. Cyclindependent kinase 5 in neurofilament function and regulation. Neurosignals 12: 252-264.
42. Ohshima, T. et al. 1996. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. USA 93: 11173-11178.
43. Dhavan, R. & L.H. Tsai. 2001. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2: 749-759.
44. Tsai, L.H. et al. 1994. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371: 419-423.
45. Tang, D. & Wang, J.H. 1996. Cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activators. Prog. Cell Cycle Res. 2: 205-216.
46. Lau, L.F. et al. 2002. Cdk5 as a drug target for the treatment of Alzheimer's disease. J. Mol. Neurosci. 19: 267-273.
47. Lee, M.S. et al. 2000. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405: 360-364.
48. Kusakawa, G. et al. 2000. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 275: 17166-17172.
49. Sun, Z. et al. 1999. Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer 86: 689-696.
50. Chrousos, G.P. 1995. The hypothalamic-pituitaryadrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332: 1351-136251.
51. Kino, T. & G.P. Chrousos. 2005. Glucocorticoid effects on gene expression. In Handbook of Stress and the Brain. T. Steckler,N.H.Kalin & J.M.H.M.Reul, Eds.: 295-311. Elsevier B.V. Amsterdam, Netherlands.
52. Holsboer, F. & N. Barden. 1996. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 17: 187-205.
53. Ahlijanian, M.K. et al. 2000. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. USA 97: 2910-2915.
54. Patrick, G.N. et al. 1999. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615-622.
55. Friedman, T.C. et al. 1996. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr. J. 43: 645-655.
56. Miller, W.L. & G.P. Chrousos. 2001. The adrenal cortex. In Endocrinology & Metabolism. P. Felig & L.A. Frohman, Eds.: 387-524. McGraw-Hill. New York, NY.
57. Buemann, B. et al. 2005. The N363S polymorphism of the glucocorticoid receptor and metabolic syndrome factors in men. Obes. Res. 13: 862-867.
58. DeRijk, R. & E.R. de Kloet. 2005. Corticosteroid receptor genetic polymorphisms and stress responsivity. Endocrine 28: 263-270.
59. Marti, A. et al. 2006. Meta-analysis on the effect of the N363S polymorphism of the glucocorticoid receptor gene (GRL) on human obesity. BMC Med. Genet. 7: 50-60.
60. Stevens, A. et al. 2004. Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J. Clin. Endocrinol. Metab. 89: 892-897.
61. Chrousos, G.P. 2004. The glucocorticoid receptor gene, longevity, and the complex disorders ofWestern societies. Am. J. Med. 117: 204-207.
62. Phillips,D.I. et al. 1998. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome? J. Clin. Endocrinol. Metab. 83: 757-760.
63. Manenschijn, L., E. L. T. van den Akker, S. W. J. Lamberts & E. F. C. Van Rossum. 2009. Clinical features associated with glucocorticoid receptor polymorphisms: an overview. Ann. N. Y. Acad. Sci. Glucocorticoids and Mood. Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In Press.
64. Spijker,A.T.&E. F. C.VanRossum. 2009. Glucocorticoid receptor polymorphisms in major depression: focus on glucocorticoid sensitivity and neurocognitive functioning. Ann. N. Y. Acad. Sci. Glucocorticoids andMood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
65. Syed, A.A. et al. 2006. Association of glucocorticoid receptor polymorphism A3669G in exon 9â with reduced central adiposity in women. Obesity (Silver Spring) 14: 759-764.
66. Van Rossum, E.F. et al. 2002. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 51: 3128-3134.
67. Van Rossum, E.F. & S.W. Lamberts. 2004. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 59: 333-357.
68. van Rossum, E.F. et al. 2004. The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition andmuscle strength in young adults. J. Clin. Endocrinol. Metab. 89: 4004-4009.
69. Papanicolaou,D.A. et al. 1998. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128: 127-137.
70. Chrousos, G.P. & T. Kino. 2007. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10: 213-219.
71. Kino, T., T. Ichijo & G.P. Chrousos. 2004. FLASH interacts with p160 coactivator subtypes and differentially suppresses transcriptional activity of steroid hormone receptors. J. Steroid Biochem. Mol. Biol. 92: 357-363.
72. Lanz, R.B. et al. 1999. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC- 1 complex. Cell 97: 17-27.
73. Kino, T. & G.P. Chrousos. 2004. Glucocorticoid and mineralocorticoid receptors and associated diseases. Essays Biochem. 40: 137-155.
74. De Martino, M.U. et al. 2004. The glucocorticoid receptor and the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor II interact with and mutually affect each other's transcriptional activities: implications for intermediary metabolism. Mol. Endocrinol. 18: 820-833.
75. Charmandari, E., T. Kino & G.P. Chrousos. 2004. Glucocorticoids and their actions: an introduction. Ann. N. Y. Acad. Sci. 1024: 1-8.
76. Kino, T., A. Vottero & G.P. Chrousos. 2001. Mineralocorticoid and glucocorticoid receptors. In Nuclear Receptor and Genetic Disease. T.P. Burris & E.R.B. McCabe, Eds.: 297-307. Academic Press. London, England.
77. Nader, N.,G.P. Chrousos & T. Kino. 2009. Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiologic implications. FASEB J. 23: 1572-1583.